- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04870554
Effects of Feeding Schedule on the Development of ICU Delirium
April 8, 2024 updated by: Deepali Dixit, Pharm.D., BCPS, BCCCP, FCCM, Rutgers, The State University of New Jersey
This study will investigate if enteric feeding schedules alter the development of delirium in Intensive Care Unit patients who have been placed on mechanical ventilation.
Delirium is an altered state of consciousness, which can involve agitation, inattention, and decreased awareness.
We will enroll Intensive Care Unit patients who have been placed on a ventilator and are being given tube feedings.
We will randomize participants into two groups: one group will receive continuous feedings via feeding tube, and the other group will receive feedings on a schedule to mimic breakfast, lunch, a snack, and dinner.
Subjects will be assessed for the development of delirium.
Subjects will also be monitored for sleep quality.
Study Overview
Detailed Description
Patients will need to have at least 48 hours of enteric feedings to be included, and will be stratified by their APACHE IV score.
Patients will be randomized into time restricted feeding vs continuous feeding by investigators, with no change in caloric intake nor nutrient content from orders.
Patients will be assessed for delirium using the CAM-ICU (Confusion Assessment Method in the Intensive Care Unit) screening tool every twelve hours.
At the time of the CAM ICU assessment, as part of the experimental design, the patient's sleep will be monitored by X8 Sleep Profiler device, placed and secured to their forehead, and the Sleep Profiler device will collect information regarding sleep quality as assessed by relative delta power, relative theta power and relative beta power.
Study Type
Interventional
Enrollment (Estimated)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Deepali Dixit, PharmD
- Phone Number: (848) 445-6825
- Email: ddixit@pharmacy.rutgers.edu
Study Locations
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08901
- Recruiting
- Robert Wood Johnson University Hospital
-
Contact:
- Deepali Dixit, PharmD
- Phone Number: 848-445-6825
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 89 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Admitted to the ICU
- Mechanically ventilated
- Receiving enteric feedings for at least 48 hours
Exclusion Criteria:
- Pregnancy
- Previously diagnosed neurocognitive disorders,
- Alcohol withdrawal and history of alcohol dependence
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Continuous Feeding
Enteric feeding will be given continuously.
|
|
Experimental: Timed Feeding
Enteric feeding will be given four times per day, approximating breakfast, lunch, a snack, and dinner.
|
All subjects will be given nutrition enterally, corresponding to their calculated nutritional needs.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of patients developing delirium.
Time Frame: 48 hours after admission to the ICU.
|
The development of delirium as measured by the CAM-ICU (Confusion Assessment Method for the ICU) protocol.
The percent of patients developing delirium will be assessed in each arm.
Delirium will be assessed every 12 hours.
|
48 hours after admission to the ICU.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in sleep quality assessed using delta power.
Time Frame: Measurement will be made from study enrollment to extubation, up to 1 week.
|
Change in relative delta power on EEG will be assessed in each arm.
|
Measurement will be made from study enrollment to extubation, up to 1 week.
|
Change in sleep quality assessed using theta power.
Time Frame: Measurement will be made from study enrollment to extubation, up to 1 week.
|
Change in relative theta power on EEG will be assessed in each arm.
|
Measurement will be made from study enrollment to extubation, up to 1 week.
|
Change in sleep quality using beta power.
Time Frame: Measurement will be made from study enrollment to extubation, up to 1 week.
|
Change in relative beta power on EEG will be assessed in each arm.
|
Measurement will be made from study enrollment to extubation, up to 1 week.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Deepali Dixit, PharmD, Rutgers Ernest Mario School of Pharmacy
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 26, 2021
Primary Completion (Estimated)
April 26, 2024
Study Completion (Estimated)
April 26, 2024
Study Registration Dates
First Submitted
April 23, 2021
First Submitted That Met QC Criteria
April 28, 2021
First Posted (Actual)
May 3, 2021
Study Record Updates
Last Update Posted (Actual)
April 9, 2024
Last Update Submitted That Met QC Criteria
April 8, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro2018001273
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ICU Delirium
-
National Taiwan University HospitalRecruiting
-
University Hospital, Basel, SwitzerlandRecruiting
-
Pomeranian Medical University SzczecinCompleted
-
National Taiwan University HospitalRecruiting
-
University Hospital, Basel, SwitzerlandCentre for Chronobiology, Transfaculty Research Platform Molecular and Cognitive...Completed
-
University Hospital, BrestBaxter Healthcare Corporation; Direction Générale de l'Offre de SoinsCompleted
-
PD Dr. Bertram SchellerGoethe University; Dr. Franz Köhler Chemie GmbH (study medication and labeling)UnknownSuspected Delirium After Elective or Emergency Heart Surgery | CAM-ICU Diagnosed DeliriumGermany
-
University of NebraskaRobert Wood Johnson FoundationCompletedImmobility | ICU DeliriumUnited States
-
University of Sao PauloTerminatedElderly | Delirium of Unknown (Axis III) Etiology | Intensive Care (ICU) MyopathyBrazil
-
Assistance Publique - Hôpitaux de ParisRecruiting
Clinical Trials on Enteric feeding
-
Guangzhou Yipinhong Pharmaceutical CO.,LTDCompletedChronic Hepatitis BChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Unknown
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Completed
-
Centre Henri BecquerelUnknownHaematological MalignancyFrance
-
Guangdong Provincial Hospital of Traditional Chinese...RecruitingCritical Illness | Nutrition Disorders | Gastrointestinal DysfunctionChina
-
University of Southern CaliforniaCompletedDiabetes Mellitus, Type 2United States
-
Guangzhou Yipinhong Pharmaceutical CO.,LTDCompleted
-
NestléCompleted